Literature DB >> 11961122

Refinement of the conformation of a critical region of charge-charge interaction between cholecystokinin and its receptor.

Xi-Qin Ding1, Delia I Pinon, Kristina E Furse, Terry P Lybrand, Laurence J Miller.   

Abstract

Insight into the molecular basis of cholecystokinin (CCK) binding to its receptor has come from receptor mutagenesis and photoaffinity labeling studies, with both contributing to the current hypothesis that the acidic Tyr-sulfate-27 residue within the peptide is situated adjacent to basic Arg(197) in the second loop of the receptor. Here, we refine our understanding of this region of interaction by examining a structure-activity series of these positions within both ligand and receptor and by performing three-dimensional molecular modeling of key pairs of modified ligand and receptor constructs. The important roles of Arg(197) and Tyr-sulfate-27 were supported by the marked negative impact on binding and biological response with their natural partner molecule when the receptor residue was replaced by acidic Asp or Glu and when the peptide residue was replaced by basic Arg, Lys, p-amino-Phe, p-guanidino-Phe, or p-methylamino-Phe. Complementary ligand-receptor charge-exchange experiments were unable to regain the lost function. This was supported by the molecular modeling, which demonstrated that the charge-reversed double mutants could not form a good interaction without extensive rearrangement of receptor conformation. The models further predicted that R197D and R197E mutations would lead to conformational changes in the extracellular domain, and this was experimentally supported by data showing that these mutations decreased peptide agonist and antagonist binding and increased nonpeptidyl antagonist binding. These receptor constructs also had increased susceptibility to trypsin degradation relative to the wild-type receptor. In contrast, the relatively conservative R197K mutation had modest negative impact on peptide agonist binding, again consistent with the modeling demonstration of loss of a series of stabilizing inter- and intramolecular bonds. The strong correlation between predicted and experimental results support the reported refinement in the three-dimensional structure of the CCK-occupied receptor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11961122     DOI: 10.1124/mol.61.5.1041

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  15 in total

1.  Transmembrane segment peptides can disrupt cholecystokinin receptor oligomerization without affecting receptor function.

Authors:  Kaleeckal G Harikumar; Maoqing Dong; Zhijie Cheng; Delia I Pinon; Terry P Lybrand; Laurence J Miller
Journal:  Biochemistry       Date:  2006-12-12       Impact factor: 3.162

2.  Novel benzodiazepine photoaffinity probe stereoselectively labels a site deep within the membrane-spanning domain of the cholecystokinin receptor.

Authors:  Elizabeth M Hadac; Eric S Dawson; James W Darrow; Elizabeth E Sugg; Terry P Lybrand; Laurence J Miller
Journal:  J Med Chem       Date:  2006-02-09       Impact factor: 7.446

3.  Probing a model of a GPCR/ligand complex in an explicit membrane environment: the human cholecystokinin-1 receptor.

Authors:  Jérôme Hénin; Bernard Maigret; Mounir Tarek; Chantal Escrieut; Daniel Fourmy; Christophe Chipot
Journal:  Biophys J       Date:  2005-12-02       Impact factor: 4.033

4.  Molecular modeling of flexible arm-mediated interactions between bacterial chemoreceptors and their modification enzyme.

Authors:  Usha K Muppirala; Susan Desensi; Terry P Lybrand; Gerald L Hazelbauer; Zhijun Li
Journal:  Protein Sci       Date:  2009-08       Impact factor: 6.725

5.  Fluorescence polarization screening for allosteric small molecule ligands of the cholecystokinin receptor.

Authors:  Kaleeckal G Harikumar; Erin E Cawston; Laurence J Miller
Journal:  Assay Drug Dev Technol       Date:  2011-03-11       Impact factor: 1.738

6.  Development of a highly selective allosteric antagonist radioligand for the type 1 cholecystokinin receptor and elucidation of its molecular basis of binding.

Authors:  Maoqing Dong; Ashton M Vattelana; Polo C-H Lam; Andrew J Orry; Ruben Abagyan; Arthur Christopoulos; Patrick M Sexton; David R Haines; Laurence J Miller
Journal:  Mol Pharmacol       Date:  2014-10-15       Impact factor: 4.436

7.  The disease-causing mutations in the carboxyl terminus of the cone cyclic nucleotide-gated channel CNGA3 subunit alter the local secondary structure and interfere with the channel active conformational change.

Authors:  Alexander V Matveev; J Browning Fitzgerald; Jianhua Xu; Anna P Malykhina; Karla K Rodgers; Xi-Qin Ding
Journal:  Biochemistry       Date:  2010-03-02       Impact factor: 3.162

Review 8.  The crystallographic model of rhodopsin and its use in studies of other G protein-coupled receptors.

Authors:  Slawomir Filipek; David C Teller; Krzysztof Palczewski; Ronald Stenkamp
Journal:  Annu Rev Biophys Biomol Struct       Date:  2003-02-05

9.  Elucidation of the molecular basis of cholecystokinin Peptide docking to its receptor using site-specific intrinsic photoaffinity labeling and molecular modeling.

Authors:  Maoqing Dong; Polo C-H Lam; Delia I Pinon; Ruben Abagyan; Laurence J Miller
Journal:  Biochemistry       Date:  2009-06-16       Impact factor: 3.162

10.  Use of multidimensional fluorescence resonance energy transfer to establish the orientation of cholecystokinin docked at the type A cholecystokinin receptor.

Authors:  Kaleeckal G Harikumar; Fan Gao; Delia I Pinon; Laurence J Miller
Journal:  Biochemistry       Date:  2008-08-13       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.